Summary
The protein binding of carbamazepine (CBZ) in vitro was assessed in sera from 47 patients with various diseases known to alterα 1-acid glycoprotein (AAG) concentration and from 20 drug-free normal control subjects. In the patient group, AAG and albumin (HSA) concentrations ranged from 6 to 74 µmol/l and from 377 to 652 µmol/l, respectively; in the controls, protein concentrations were less variable, ranging from 11 to 26 µmol/l for AAG and from 623 to 754 µmol/l for HSA. In both the patient and the combined patient and control groups, free CBZ fractions were inversely correlated with the serum AAG concentration (r=−0.62). No significant relationship could be found between the free CBZ fraction and the serum HSA concentration. The free CBZ fraction was moderately but significantly decreased in patients with AAG levels above 26 µmol/l (the highest value found in controls) as compared either to patients with a normal AAG concentration or to control subjects (19±5% vs 23±4% and 23±2%), despite the finding of a higher HSA concentration in the control group. The data confirm AAG as an important determinant of interindividual variability in serum CBZ binding.
Similar content being viewed by others
References
Paxton JW (1983)α 1-acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol 5: 635–648
Mackichan JJ, Zola EM (1984) Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin andα 1-acid glycoprotein. Br J Clin Pharmacol 18: 487–493
Contin M, Riva R, Albani F, Perucca E, Lamontanara G, Baruzzi A (1985)α 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy. Eur J Clin Pharmacol 29: 211–214
Riva R, Contin M, Albani F, Baruzzi A, Lamontanara G (1985) Highα 1-acid glycoprotein concentrations in serum of epileptic children treated with carbamazepine. Clin Chem 31: 150
Piafsky KM (1980) Disease induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 5: 246–262
Piafsky KM, Mpamugo L (1981) Dependence of neonatal binding onα 1-acid glycoprotein concentration. Clin Pharmacol Ther 29: 272
Wood M, Wood AJJ (1981) Changes in plasma drug binding andα 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 29: 522–526
Contin M, Riva R, Albani F, Perucca E, Baruzzi A (1985) Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: Interference with the 10,11-epoxide metabolite. Ther Drug Monit 7: 46–50
Cramer JA, Mattson GF, Collins JF, Browne FR, V.A. Epilepsy Cooperative Study Group (1984) Correlation between phenytoin and carbamazepine free fraction and serum albumin. Epilepsia 25: 674–675
Hooper WD, Dubetz DK, Bochner F, Cotter LM, Smith GA, Eadie MJ, Tyrer JH (1975) Plasma protein binding of carbamazepine. Clin Pharmacol Ther 17: 433–440
Barre J, Hovin G, Rosenbaum J, Zini R, Dhumeaux D, Tillement JP (1984) Decreasedα 1-acid glycoprotein in liver cirrhosis: Consequences for drug protein binding. Br J Clin Pharmacol 18: 652–653
Piafsky KM, Borga O, Oder-Cederlof I, Johansson C, Sjöqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasmaα 1-acid glycoprotein. N Engl J Med 299: 1435–1439
Perucca E, Grimaldi R, Crema A (1985) Interpretation of drugs levels in acute and chronic disease states. Clin Pharmacokinet 10: 498–513
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baruzzi, A., Contin, M., Perucca, E. et al. Altered serum protein binding of carbamazepine in disease states associated with an increasedα 1-acid glycoprotein concentration. Eur J Clin Pharmacol 31, 85–89 (1986). https://doi.org/10.1007/BF00870992
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00870992